50% of SFH’s programme beneficiaries are the poor.

50% of rural pregnant women and children under 5 sleep under long lasting insecticide treated nets in at least two focus states.
Modern contraceptive prevalence rate increases from 11% to 16%.

Consistent condom use among high risk groups increases by 20%.

SFH MISSION

Society for Family Health has a mission to empower Nigerians, particularly the poor and vulnerable to lead healthier lives...more 

SFH PRODUCTS

Artemisinin-based Combination Therapies (ACTs)
Artemisinin-based Combination Therapies (ACTs) are a combination of Artemisinin with another anti-malaria medicine. They are presently the most effective treatment for uncomplicated Plasmodium falciparum malaria. Artemisinin is a plant-based drug extracted from the source plant Artemisia annua. Derivatives of Artemisinin include Artemether and Artesunate. The World Health Organisation (WHO) strongly discourages the use of Artemisinin alone or either derivative alone as a malaria treatment.  When combined with another medicine, however, Artemisinin-based Combination Therapies form a dual offensive against the malaria parasite, P. falciparum. The treatment of malaria with Artemisinin or its derivatives without another drug is known as monotherapy.  Monotherapy is discouraged because it would set off resistance of the malaria parasite to Artemisinin and progressively diminish the effectiveness of ACTs against malaria. Approved combinations include Artemether and Lumefantrine (AL) and Artesunate and Amodiaquine (AA), marketed under several brand names.  ACT brands on the Nigerian market include Coartem (AL), Lonart ®(AL), Dart® (AA), Diasunate® (AA), Coarsucam® (AA).
Older malaria medicines, such as Chloroquine and Sulphadoxine Pyrimethamine are becoming increasingly inadequate as effective treatments against malaria. Yet because of their low costs, they are still widely used for treating malaria. The National Malaria Treatment Policy recommends ACTs as the first line treatment for malaria in Nigeria.  However, only about one in five malaria cases are treated with ACTs, which cost much more than the older medicines. 
Society for Family Health, through the Global Fund Malaria and Pre-Packaged Therapy (PPT) projects, is working to ensure broad access to ACTs in Nigeria. This means that affordable ACTs will be provided to more communities in Nigeria.
Through the Global Fund, SFH is providing Artemether Lumefantrine (AL), sold under the brand name, Coartem®.  Global Fund ACTs are available for people of all ages , and will be marketed in all of Nigeria’s 36 states and its FCT.
The PPT project provides Artesunate Amodiaquine (AA) Winthrop® for children aged 5 years and under—a specially vulnerable group to life-threatening malaria.  
These drugs are provided at substantially subsidised prices so that the most needy populations can treat malaria with the most effective medicines.  Both projects are being implemented in the private sector through clinics, pharmacies and patent medicine vendors. These are especially important channels because a greater percentage (>60%) of people access their medicines from the private sector, which  provides only about 5% of ACTs. These programs aim to  make ACTs the first choice for malaria treatment, not solely through the provision of subsidized drugs, but further through behaviour change and health education programs, which inform on the value of Artemisinin combination therapies as the best treatment for malaria.